Lv3
250 积分 2024-09-07 加入
A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
17小时前
待确认
Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria
24天前
已完结
The global burden of chronic urticaria for the patient and society*
25天前
已完结
Chronic urticaria in Chinese population: a hospital-based multicenter epidemiological study
25天前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
1个月前
已完结
系统性硬化病流行病学研究进展
3个月前
已完结
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024
3个月前
已完结
Global, regional, and national incidence and prevalence of systemic sclerosis
3个月前
已完结
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
3个月前
已完结
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]
3个月前
已完结
皖公网安备34019202002308
